Androgen deprivation therapy and competing risks

JAMA

Volumn 306, Issue 21, 2011, Pages 2382-2383

  Kelly, William K ^a   Gomella, Leonard G ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST;

ANDROGEN DEPRIVATION THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG SAFETY; EDITORIAL; HEART DEATH; HEART INFARCTION; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; LIBIDO DISORDER; LIPID COMPOSITION; METABOLIC SYNDROME X; OSTEOPENIA; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; SUDDEN DEATH; TREATMENT DURATION; WEIGHT GAIN;

EID: 83055163729     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1791     Document Type: Editorial

References (14)

1. Stege R. Potential side-effects of endocrine treatment of long duration in prostate cancer. Prostate Suppl. 2000;10:38-42.
2. Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010;121(6):833-840.
3. Smith MR. Treatment-related osteoporosis in men with prostate cancer. Clin Cancer Res. 2006;12(20 pt 2):6315s-6319s. (Pubitemid 44703810)
4. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448-4456. (Pubitemid 46630983)
5. Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110(7):1493-1500. (Pubitemid 47463063)
6. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99(20):1516-1524. (Pubitemid 351767235)
7. US Food and Drug Administration. FDA Drug Safety Communication: Update to Ongoing Safety Review of GnRH Agonists and Notification to Manufacturers of GnRH Agonists to Add New Safety Information to Labeling Regarding Increased Risk of Diabetes and Certain Cardiovascular Diseases. http://www.fda.gov/Drugs/ DrugSafety/ucm229986.htm. Accessed November 10, 2011.
8. Nguyen PL, Je Y, Schutz FAB, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306(21):2359-2366.
9. Van Hemelrijck M, Garmo H, Holmberg L, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol. 2010;28(21):3448-3456.
10. Chao HH, Mayer T, Concato J, Rose MG, Uchio E, Kelly WK. Prostate cancer, comorbidity, and participation in randomized controlled trials of therapy. J Investig Med. 2010;58(3):566-568.
11. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003;95(13):981-989. (Pubitemid 36896715)
12. Gomella LG, Lin J, Hoffman-Censits J, et al. Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience. J Oncol Pract. 2010;6(6):e5-e10.
13. Ferrante JM, Balasubramanian BA, Hudson SV, Crabtree BF. Principles of the patient-centered medical home and preventive services delivery. Ann Fam Med. 2010;8(2):108-116.
14. Reid RJ, Coleman K, Johnson EA, et al. The group health medical home at year two: cost savings, higher patient satisfaction, and less burnout for providers. Health Aff (Millwood). 2010;29(5):835-843.